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1Tasavertainen työpanos. 
 
Munasarjasyöpä on gynekologisista syövistä huonoennusteisin. Huonosti erilaistunut seroosi karsinooma 
(high-grade serous carcinoma, HGSC) on munasarjasyövän yleisin histologinen alatyyppi, jolle on tyypillistä 
aggressiivinen levittäytyminen. Munasarjasyöpäpotilaiden viiden vuoden elossaololuku on vain noin 45 %. 
Ennustetta huonontavat myöhäinen diagnosointi, mikä johtuu spesifisten oireiden ja toimivien 
seulontamenetelmien puutteesta, sekä hoitoresistenssin kehittyminen.  Siksi uusia hoitomuotoja, kuten 
immuno-onkologisia hoitoja, tarvitaan. Tuumorin mikroympäristön (tumor microenvironment, TME) ja siinä 
esiintyvien immuunisolujen toiminnan tunteminen on tärkeää immuno-onkologisten hoitojen kehittämiseksi ja 
hoidosta hyötyvien potilaiden tunnistamiseksi. Digitaalisilla kuva-analyysimenetelmillä (digital image analysis, 
DIA) voidaan lisätä TME:n immuunisolujen määrityksen luotettavuutta ja toistettavuutta. 
Tämän tutkimuksen tarkoituksena oli selvittää immuunisolujen ilmentymistä HGSC-kudoksen TME:ssä 
retrospektiivisestä potilaskohortista hyödyntäen virtuaalimikroskopiaa (whole slide imaging, WSI) ja digitaalista 
kuva-analyysiä. 
Tutkimusaineisto koostui Tampereen yliopistollisessa sairaalassa (Tays) 2001–2013 leikattujen HGSC-
potilaiden (n=67) kasvainnäytteistä (formaliinifiksoidut, parafiinipedatut FFPE-blokit). Tuumorinäytteille on 
tehty seuraavat immunohistokemialliset värjäykset tunnistaen erilaisia TME:n immuunisoluja: CD4 (auttaja-T-
lymfosyytit), CD8 (tappaja-T-lymfosyytit), FoxP3 (säätelijä-T-lymfosyytit), grantsyymi B (aktivoituneet 
lymfosyytit ja luonnolliset tappajasolut), CD68 (M1- ja M2-makrofagit) ja CD163 (M2-makrofagit). Värjäykset 
on analysoitu digitaalisesti QuPath 0.1.2- ja ImageJ-ohjelmilla ja tulokset on yhdistetty potilasasiakirjoista 
kerättyihin, kliinispatologisiin tietoihin. 
Tutkimuksessa CD8-, grantsyymi B- ja CD163-positiivisten solujen suuremmat määrät tuumorikudoksessa 
olivat yhteydessä pidempään tautivapaaseen aikaan (progression free survival, PFS). Kuitenkin vain sekä 
CD8- että grantsyymi B -solujen yhtäaikainen suurempi määrä oli yhteydessä pidempään PFS:iin 
monimuuttuja-analyysissa (HR=0,287; p=0,002). Lisäksi neoadjuvanttikemoterapian (neoadjuvant 
chemoterapy, NACT; ennen leikkausta annettu sytostaattihoito) jälkeen otetuissa näytteissä FoxP3+ solujen 
määrä oli pienempi kuin ennen hoitoa otetuissa tai primaarileikattujen potilaiden näytteissä (Fisherin tarkka 
testi; p=0,013). 
CD8- ja grantsyymi B -solujen yhtäaikainen ilmentyminen tuumorikudoksessa oli yhteydessä 
munasarjasyövän parempaan ennusteeseen viitaten mahdollisesti TME:n aktivoituneeseen, 
syövänvastaiseen immuunivasteeseen. NACT voi vaikuttaa TME:n immuunisolujen jakaumaan ja näin ollen 
kemoterapian ja immuno-onkologisten hoitojen tehoon.  
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1 ABSTRACT 
 
 
1.1 Objectives 
 
Ovarian cancer (OC) is the most lethal of gynecological cancers with five-
year survival rate of only ca. 45 %. The most common histologic subtype is 
high-grade serous carcinoma (HGSC), which typically is presented with 
advanced stage and development of chemoresistance. Therefore, new 
treatment options, including immunotherapies, are needed. Understanding 
the features of the immune cell populations and their interaction in the tumor 
microenvironment (TME) is essential for developing personalized treatment 
options and finding predictive biomarkers. Digital image analysis (DIA) may 
enhance the accuracy and reliability of immune cell infiltration assessment in 
the TME. 
 
The aim of this study was to characterize TME in a retrospective cohort of 
high-grade serous ovarian cancer samples with whole-slide imaging (WSI) 
and digital image analysis (DIA).  
 
1.2 Methods 
 
Formalin-fixed paraffin-embedded (FFPE) HGSC tumor tissue samples 
(n=67) were analyzed for six different immunohistochemical (IHC) stainings: 
CD4, CD8, FoxP3, granzyme B, CD68 and CD163. The stained sample 
slides were scanned into a digital format and assessed using QuPath 0.1.2. 
and ImageJ softwares. Staining patterns were associated with 
clinicopathological data.  
 
1.3 Results 
 
The higher numbers of CD8+, CD163+ and granzyme B+ immune cells were 
associated with survival benefit when analyzed individually, while high levels 
of both CD8+ and granzyme B+ tumor-infiltrating lymphocytes (TILs) was an 
independent prognostic factor in Cox multivariate regression analysis 
(median PFS; HR=0.287, p=0.002). In addition, the given neoadjuvant 
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chemotherapy (NACT) was associated with lower FoxP3+ TIL density 
(Fisher’s exact test, p=0.013).  
 
1.4 Conclusions 
 
Tumors having high amount of both CD8+ and granzyme B+ TILs showed 
better prognosis, possibly reflecting an activated immune state in the TME. 
The combined positivity of CD8 and granzyme B warrants further 
investigation with respect to predicting response to immune therapy. NACT 
may have an effect on the TME and therefore on the response to immuno-
oncologic or chemotherapy treatments.  
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2 INTRODUCTION 
 
 
Ovarian cancer (OC) is the third most common and the most lethal 
gynecological cancer (1). High-grade serous carcinoma (HGSC) is the most 
common histological subtype, characterized by aggressive dissemination 
(2,3). The standard treatment of OC is primary cytoreductive (debulking) 
surgery (PDS), followed by platinum-based combination chemotherapy with 
or without bevacizumab (4-6). In some cases with advanced disease, 
neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) 
may be considered (4,7,8). The poor prognosis in OC (five-year survival ca 
45 %) is caused by late diagnosis (67–75 % at FIGO III–IV) due to lack of 
specific symptoms and screening methods and by the development of 
chemoresistance over cumulative treatment lines (2,4). Most of the patients 
respond to primary treatment. However, nearly 80 % of patients with 
advanced disease will relapse and recurrence is mostly incurable. (4) 
Despite the recent paradigm shift in front-line OC treatment with PARP 
inhibitors (9-11), there is still urgent need for new OC treatment options, 
including immunotherapies. Immune cells and immunoregulatory molecules 
present in the tumor microenvironment (TME) are involved both in anti-tumor 
immune responses of the host and in immunosuppressive mechanisms 
promoting cancer progression. Understanding the nature and characteristics 
of TME is essential for developing immuno-oncologic treatment options and 
discovering predictive biomarkers for patient selection. (12-14) 
 
Tumor-infiltrating lymphocytes (TILs) infiltrate to the tumor epithelium 
(intraepithelial, ieTILs) or locate at the peritumoral stroma (stromal, sTILs) 
(15). Intraepithelial CD3+ TILs (T cells) have been associated with improved 
patient outcome in OC (16-21). When assessing the subsets of T cells, 
particularly CD8+ TILs (cytotoxic T-lymphocytes, Tc or CTL) (17-20,22-26), 
and, in some studies, CD4+ TILs (T helper, Th) (22) have been associated 
with favourable prognosis. Activated CTLs and natural killer (NK) cells 
eliminate cancer cells by secreting cytolytic enzymes, including granzyme B 
(27). 
FoxP3+ regulatory T cells (Tregs) may in turn suppress anti-tumor immunity 
(15). The reports of impact of Tregs on prognosis of OC or other cancers 
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have been contradictory (18,19,24,28-30). Tumor-associated macrophages 
(TAMs) are further divided into M1 and M2 subtypes, of which M1 TAMs 
contribute to elimination of cancer cells, whereas anti-inflammatory M2 type 
is involved with tissue repair, angiogenesis and cancer progression (31). 
There is no clear consensus on the role of M1 and M2 type of TAMs in OC, 
but according to available data, CD68+ (M1 and M2) TAM density may not 
act as prognostic factor (19,21,32-34). 
 
In addition, administration of NACT may alter the immune cell populations in 
TME. Although previously considered immunosuppressive, NACT has more 
recently been found to have anti-tumor immunity enhancing effects. (35) 
However, results considering the impact of NACT on the immune cells in OC 
TME and the prognostic significance of post-NACT TILs have been highly 
variable (20,25,30,36,37). Immune cell infiltration in OC has been studied 
extensively, yet results considering the prognostic significance of immune 
cells in the TME are highly variable (15,18). Currently, there are no 
established cut-off values or analyzing methods for assessment of TILs, 
which may weaken the reproducibility of the studies. The use of whole slide 
imaging (WSI) and digital image analysis (DIA) has been found to increase 
the reliability and accuracy of assessment of immune cells when compared 
to manual analysis and semi-quantitative scales (38,39). Therefore, the 
present study focusing on HGSC was set up to clarify, which immune cells 
or biomarkers present in TME are associated with clinical outcome. For 
optimal accuracy, WSI and DIA were used in the analyses. 
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3  MATERIALS AND METHODS 
 
 
3.1  Patients and samples 
 
The study was carried out at the Tampere University Hospital (TAUH) and 
the Faculty of Medicine and Health Technology, University of Tampere, 
Tampere, Finland. The study protocols have been approved by the Regional 
Ethics Committee of the Expert Responsibility area of Tampere University 
Hospital (identification codes: ETL-R09108 and ETL-R11137). All the study 
patients have provided a signed informed consent. 
 
The present retrospective study cohort is consisted of tumor samples from 
two different cohorts of epithelial ovarian cancer (EOC) patients who had 
undergone primary or interval debulking surgery in TAUH during 2001–2009 
and 2011–2013. Patients were recruited to the study when they were being 
treated with chemotherapy in either adjuvant or recurrent setting (older 
surgery cohort of 2001–2009) or when they have been scheduled for EOC 
surgery (surgery cohort of 2011–2013). The morphological and histological 
findings from the available and representative archival surgical tumor 
specimens were assessed by experienced pathologists at the Department of 
Pathology of TAUH. Only samples from patients with histologically verified 
high-grade ovarian cancer were included in the final study cohort, which 
consisted of 67 high-grade ovarian cancer samples having sufficient tumor 
tissue content and technical quality for analyses. 
 
Clinical, pathological and follow-up data were collected from the patient 
records. As the patients were operated prior to 2014, the staging was 
adjusted to the FIGO 2014 staging classification. Surgical outcome was 
classified as following: R0 = no macroscopic residual tumor, R1 = residual 
tumor < 1 cm, R2 = residual tumor > 1 cm. Median age at diagnosis was 63 
years (range 38–78). Almost all patients (n=64; 96 %) had verified HGSC 
histology. Most of the patients (n=60; 90 %) presented with an advanced 
stage disease (FIGO III/IV) with a median OS of 52 months (range 11–163) 
and PFS of 16 months (range 5–124). The main clinico-pathological 
characteristics of the study patients are summarized in Table 1. 
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3.2 Immunohistochemical stainings and 
interpretation 
 
The HGSC tissue samples were formalin-fixed and paraffin-embedded 
(FFPE) prior to immunohistochemical (IHC) stainings. FFPE samples were 
cut into 3–4 μm thick sequential sections that were then baked, 
deparaffinized and pretreated by boiling them in Tris-EDTA buffer (pH 9) at + 
98 °C for 15 minutes for epitope retrieval.  Immunohistochemical stainings 
were performed by indirect HRP-based detection technique. Six IHC 
stainings were performed: CD4, CD8, FoxP3, granzyme B, CD68 and 
CD163. The antibodies, clones and used dilutions are presented in Table 2. 
The tissue sections were counterstained with Mayer’s hematoxylin (Oy 
FFChemicals Ab, Haukipudas, Finland) to give contrast for positive staining 
reaction visualized as brown DAB precipitate. Staining protocols were carried 
out with Autostainer 480 (Lab Vision, CA, USA) automated immunostainer. 
 
The stained sample slides were scanned into a digital format by using 
Hamamatsu NanoZoomer S60 Digital Slide Scanner. The digital whole slide 
images (WSI) were analyzed using QuPath 0.1.2. DIA software (40). Three 
hot spot areas of 1 mm² tumor tissue were selected from each slide. For 
CD4, CD8, FoxP3 and granzyme B stainings, the positively stained 
intraepithelial immune cells in each 1 mm² area were counted digitally by 
using QuPath. For optimal accuracy, the cell counts were occasionally 
revised manually. For CD68 and CD163 stainings, the hot spot areas were 
selected using QuPath and the percentages of positively stained areas were 
calculated by using ImageJ (41). The mean cell count or positively stained 
proportion of the three selected hot spots was calculated for each image. The 
above-mentioned analyses were performed separately by an experienced 
cell biologist (SL) and the first author (TJ). The mean of the obtained results 
was used for statistical analyses. Any discrepancies between the analyses 
were discussed until a consensus was achieved. 
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3.3 Statistical analyses 
 
Statistical analyses were performed using IBM SPSS Statistics 25.0 
software. Progression free survival (PFS) was defined as time from diagnosis 
to the first recurrence. Overall survival (OS) was defined as time from 
diagnosis to death. Data were censored to the last follow-up for patients that 
were alive and/or had no recurrence at the time of data collection.  
 
Kolmogorov-Smirnov test and Shapiro-Wilk tests were used for determining 
the normality of the variable distributions. Medians of cell densities or areas 
stained / 1mm² tumor tissue were compared between groups using Mann-
Whitney U-test. Chi-square test and Fisher’s exact test were used when 
comparing log transformed cell densities or areas stained as dichotomous 
variables. Kaplan-Meier method was used for analyzing cumulative survival, 
and differences in survival between groups were compared by log-rank test. 
A cut-off value for cell densities or areas stained was set at the lowest 10th 
percentile. Hazard ratios (HR) and 95 % confidence intervals (CI) were 
analyzed by Cox proportional hazards regression model. Cell densities or 
areas stained / 1 mm² tumor tissue were log transformed when analyzed as 
continuous variables in regression models. Cell densities that showed a 
significant correlation with survival in univariate Cox regression analysis, 
were entered to a multivariate analysis with known prognostic factors: size 
of residual tumor after surgery (R0 or R1/R2), NACT and stage at diagnosis 
(FIGO I/II or III/IV). P-value ≤ 0.05 was considered statistically significant.  
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Table 1: Patient characteristics     
    
Total 
(n=67) 
Age at diagnosis (y); median (range)  63 (38–80) 
Stage at diagnosis; n (%)     
  I 1 (1.5) 
  IIA/IIB 6 (9.0) 
  IIIA/IIIB 3 (4.5) 
  IIIC 41 (61.2) 
  IVA/IVB 16 (23.9) 
Grade; n (%)     
  1–2 0 (0.0) 
  3 67 (100.0) 
Histology; n (%)     
  Serous 63 (94.0) 
  Transitional cell 1 (1.5) 
  Other or undefined epithelial 3 (4.5) 
Ca 12-5 prior to treatment (kU/l); median (range) 719 (11–8909) 
Ca 12-5 after treatment (kU/l); median (range) 16 (5–904) 
BRCA status; n (%)     
  Wild type 7 (10.4) 
  BRCA1 0 (0) 
  BRCA2 3 (4.5) 
  Not tested 57 (85.1) 
Anti-inflammatory medication; n (%)     
  Yes 4 (6.0) 
  No 63 (94.0) 
Other cancers, n (%)     
  Yes, breast  4 (6.0) 
  Yes, other than breast 4 (6.0) 
  No 59 (88.1) 
Residual disease; n (%)     
  R0 16 (23.9) 
  R1 12 (17.9) 
  R2 39 (58.2) 
First-line chemotherapy; n (%)     
  Paclitaxel-carboplatin 23 (34.3) 
  Paclitaxel-carboplatin-bevacizumab 11 (16.4) 
  
Paclitaxel-carboplatin, switched to another platinum-based during first-line 
treatment 27 (40.3) 
  Other platinum-based 6 (9.0) 
First-line chemotherapy cycles; median (range) 6 (4–18) 
Neoadjuvant chemotherapy; n (%)     
  Yes 15 (22.4) 
  No 52 (77.6) 
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Overall survival (m); median (range) 52 (11–163) 
Progression free survival (m); median (range) 16 (5–124) 
Platinum free interval (m); median (range) 10 (0–120) 
Alive; n (%)     
  Yes 14 (20.9) 
  No 53 (79.1) 
Recurrence; n (%)     
  Platinum sensitive (complete, 12 m) at first recurrence 22 (34.3) 
  Platinum sensitive (partial, 6–12 m) at first recurrence 16 (23.9) 
  Platinum resistant at first recurrence 21 (31.3) 
  No recurrence 8 (11.9) 
 
 
Table 2  
Antibodies used for immunohistochemical stainings 
 
Antibody  Detectable cells Clone Host species Manufacturer  Dilution 
FoxP3 Tregs 236A/E7  Mouse mAb Abcam 1:100 
Granzyme B activated lymphocytes and 
NK cells 
BSR150  Rabbit mAb Nordic Biosite 1:300 
CD4 Th BSR4  Rabbit mAb Nordic Biosite 1:300 
CD8 Tc (CTL) BSR5  Rabbit mAb Nordic Biosite 1:200 
CD68 M1 and M2 macrophages KP1 Mouse mAb Zeta Corporation 1:1200 
CD163 M2 macrophages Ed-Hu1 Mouse mAb Bio-Rad 1:700 
Abbreviation: mAb = monoclonal antibody. 
 
  
10 
 
4 RESULTS 
 
 
The final study cohort consisted of 67 high-grade ovarian cancer samples. 
The sample topography is presented in Table 3. Most of the analyzed 
samples originated from the adnexa (89.6 %). High individual variation in the 
densities of CD4+ (0–2416), CD8+ (1–4020) and granzyme B+ cells (3–
3028) was observed. Median cell densities (CD4+, CD8+, FoxP3+ and 
granzyme B+) or positively stained areas (CD68+ and CD163+) are 
summarized in Table 4 and examples of immunostainings are presented in 
Figure 1. A correlation between prolonged median PFS (17.00 vs 9.00 
months for all comparisons) and higher combined CD8+ and granzyme B+ 
(p=0.003), granzyme B+ (p=0.002), CD8+ (p=0.018) and CD163+ (p=0.004) 
cell densities was observed in Kaplan-Meier analysis (Figure 2). The higher 
number of granzyme B+ cells was correlated with prolonged median PFS 
also in univariate Cox proportional hazard regression (HR=0.820, p=0.032; 
Table 5) but only the combined higher amount of both CD8+ and granzyme 
B+ cells was correlated with prolonged median PFS both in univariate 
(HR=0.334, p=0.006) and multivariate (HR=0.287, p=0.002) Cox regression 
analysis (Table 5). None of the studied immunomarkers was associated with 
OS (data not shown) or with clinical factors (data not shown).  
 
Post-NACT tumor samples (n=7) presented with lower densities of FoxP3+ 
cells (Figure 1 K–L; cut-off 10th percentile (9 cells / mm2), Fisher’s exact test, 
p=0.013). The median densities of CD4+ and granzyme B+ TILs were more 
than 50 % lower in post-NACT samples, but the differences between groups 
were not statistically significant (data not shown).  
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Table 3     
Sample topography     
                Total (n=67) 
    n (%) 
Ovary 45 (67.2) 
Fallopian tube 5 (7.5) 
Adnexa (not otherwise specified) 10 (14.9) 
Uterine serosa, tubal serosa 1 (1.5) 
Omentum 2 (3.0) 
Peritoneum 1 (1.5) 
Sigmoid colon 1 (1.5) 
Topography unknown 2 (3.0) 
 
 
Table 4     
Cell densities¹ or percentages of areas stained² / 1 mm² tumor tissue; median (range) 
  
  
    Median (Range) 
FoxP31 99 (0–497) 
Granzyme B1 238 (3–3028) 
CD41   180 (0–2416) 
CD81   328 (1–4020) 
CD682   12 (2–43) 
CD1632 10 (0–35) 
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Table 5             
Cox proportional hazards regression 
 Univariate Multivariate 
  Exp (B) 95 % CI p  Exp (B) 95 % CI p  
NACT             
no reference     reference     
yes 2.682 1.447–4.973 0.002 2.275 1.438–5.165 0.002 
Optimal cytoreduction             
no (R1/R2) reference     reference     
yes (R0) 0.409 0.209–0.798 0.009 0.369 0.183–0.744 0.005 
Stage             
I/II reference     reference     
III/IV 3.588 1.111–11.590 0.033 2.045 0.606–6.900 0.249 
Age 1.002 0.973–1.033 0.886       
FoxP3 0.908 0.748–1.101 0.327       
Granzyme B 0.820 0.684–0.984 0.032       
CD4 0.993 0.855–1.154 0.932       
CD8 0.934 0.794–1.098 0.406       
CD68 0.914 0.550–1.521 0.730       
CD163 0.719 0.475–1.088 0.118       
CD8+ and granzyme B+             
no reference     reference     
yes 0.334 0.153–0.730 0.006 0.287 0.127–0.648 0.003 
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E F 
Figure 1. Examples of immunostaining patterns.  
Granzyme B staining , low (5 positive cells / mm2, A) and high (1312 positive cells / mm2, B);  CD4 staining, low (4 
positive cells / mm2, C) and high (1438 positive cells / mm2, D); CD8 staining, low (2 positive cells / mm2, E) and high 
(926 positive cells / mm2, F); CD68 staining, low (positively stained area 4 %, G) and high (positively stained area 25 %), 
CD163 staining, low (positively stained area 1 %, I) and high (positively stained area 20%, J); FoxP3 staining, high (207 
positive cells / mm2, treatment naïve, K) and low (7 positive cells / mm2, NACT treated, L). 
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C D 
Figure 2. Kaplan-Meier analyses. 
A) Granzyme B; cut-off 10th percentile (16 cells / mm2). Log-rank p=0.002. B) CD8; cut-off 10th percentile (28 cells 
/ mm2). Log-rank p=0.018. C) CD163; cut-off 10th percentile (3 %/mm2). Log-rank p=0.004. D) CD8; cut-off 10th 
percentile (28 cells / mm2) and granzyme B: cut-off 10th percentile (16 cells / mm2). Log-rank p=0.003.  
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5 DISCUSSION 
 
 
Here, we report the results of characterization of various TME 
immunomarkers in a cohort of high-grade serous ovarian cancer patients. 
According to our results, combined high CD8 and granzyme B expression 
correlated with prolonged PFS. Granzyme B is considered as the most 
important cytolytic enzyme by which activated NK cells and CD8+ TILs 
destroy tumor cells (27). The prognostic benefit of CD8+ TILs has been 
previously shown in many studies (17-20,22-26). However, the association 
of CD8+ TILs with improved survival has not been systematically shown in 
OC throughout all patient subgroups (25,30). The higher amount of positive 
CD8 and granzyme B cells showed statistical significance with longer PFS in 
multivariate analysis in the present study. This might imply that activated NKs 
and CTLs or other TILs confer the immunogenic phenotype associated with 
improved survival and that the activation status of CTLs may be as important 
as the cell density or even more important (27,30). Previously, Milne et al. 
(19)  found that granzyme B infiltrates were highly correlated with CD8 TILs 
while the expression of NK cell markers was low, indicating that granzyme B 
is mostly expressed by T cells in the TME of HGSC and therefore the 
combined positivity of both CD8 and granzyme B may represent a surrogate 
marker of activated immune state in the TME. Previously, there has been 
relatively little data considering the granzyme B expression, or simultaneous 
expression of CD8 and granzyme B in the TME and OC prognosis, and 
therefore the results reported here make a valuable addition to the existing 
data. It has been shown that higher post-chemotherapy granzyme B+ / 
FoxP3+ cell ratio was associated with better prognosis in HGSC (30). In 
addition, a trend towards a positive correlation between granzyme B+ cells 
and PFS in both post-NACT (30) and treatment naïve (19) OC tumors has 
been reported. 
 
Here CD4+ or FoxP3+ TILs were not correlated with prognosis. The previous 
data has been also contradictory with respect to CD4+ TILs and prognosis 
(19,22). The previous results concerning the prognostic impact of FoxP3+ T 
cells are also variable (18,19,24,28-30). One explanation is that although 
FoxP3+ TILs are considered immunosuppressive, FoxP3+ TIL density has 
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been found to be highly correlated with other TIL densities, possibly reflecting 
a strong overall T-cell mediated immune response (19). CD68+ TAM density 
had no correlation with prognosis in our study. Similarly, various previous 
studies (19,21,32-34) confirmed no correlation between CD68+ TAMs and 
OC prognosis. We report here that CD163+ TAMs (M2) were correlated with 
longer PFS. When analyzing multiple histologic types of OC, CD163+ 
macrophages have been associated with worse prognosis (33,34). However, 
in two studies with only HGSC patients, controversially, CD163+ TAMs 
associated with neutral (20) or even favorable (21) prognosis. Although 
current consensus is that M2 TAMs are immunosuppressive and promote 
cancer progression (31), the characterization of macrophages into M1 and 
M2 types may be excessively simplified (21). 
 
The results concerning post-NACT samples should be interpreted with 
caution since the samples are not sequential, and the number of samples 
was small. However, WSI and DIA methodology confers reliability and the 
results should not be therefore omitted. We show here that FoxP3+ cell 
density was significantly smaller in post-NACT samples compared to 
treatment naïve specimens. The densities of CD4+ and granzyme B+ TILs 
were considerably smaller in post-NACT samples, as well, but the statistical 
power was insufficient to show statistical significance. In two separate 
studies with paired HGSC tumor samples, the density of FoxP3+ TILs 
remained unchanged after NACT, while an increase in CD8+ and CD3+ TILs 
(37), or CD8+, CD4+ and granzyme B+ TILs (30) was observed. In an 
analysis of unpaired HGSC samples, a decrease in CD3+ sTILs and a trend 
toward higher ieTIL density post-NACT was observed (20). Overall, due to 
methodological differences (paired or unpaired samples, different antibodies 
and scoring systems, whole-slide imaging or tumor-array technology with 
tumor punches, different histological subgroups) the results concerning the 
effects of chemotherapy on TME have been very diverse and high individual 
variation between patients has been shown (20,25,30,36,37).  There has 
been also discussion whether a true comparison between pre- and post-
NACT tumors can be performed, since the tumor content or morphology 
changes tremendously after chemotherapy (42). However, NACT can alter 
TME and therefore potentially affect the response to both conventional 
chemotherapy and immune-oncological therapies. Here we show changes 
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that can be interpreted as both boosting immunity and silencing it and 
therefore the changes on TME induced by NACT represents an important 
subject of future studies. Overall, the immune cell counts in post-NACT 
samples tended to be smaller than in treatment naïve specimens. 
Additionally, NACT and IDS were correlated with shorter PFS and OS when 
compared to PDS and adjuvant chemotherapy, possibly reflecting to that 
NACT is administered to patients having an advanced, inoperable disease. 
 
A strength of the present study is the homogeneity of the patient cohort: all 
patients had a high-grade carcinoma. Almost all (96 %) patients had HGSC 
and 90 % presented with an advanced stage disease. In various previous 
studies, multiple histological subtypes have been analyzed. As grade 2 
tumors were previously considered as high grade, in some studies with 
mostly or exclusively HGSC patients the patient cohort has consisted with 
both grade 2 and 3 tumors, enhancing the heterogeneity.  
 
The use of WSI and DIA increased the accuracy and reliability of the results. 
Using QuPath (40) and ImageJ (41) softwares, it was possible to scroll the 
WSI and compare exact cell counts (CD4+, CD8+, FoxP3+ and granzyme 
B+) and percentages of positively stained areas (CD68+, CD163+) rather 
than use a semi-quantitative scale for estimating the cell counts or the extent 
of the staining. The use of DIA has been shown to increase the accuracy of 
the assessment when compared with the use of a semi-quantitative scale 
(38,39). To our knowledge, this report is one of the few studies using WSI 
and DIA in a cohort of HGSC in assessment of TME content. Additionally, 
methods presented in this study could be applicable for clinical diagnostics. 
 
Our study has also limitations. First, the patient cohort was rather small 
(n=67). The number of optimally resected patients was small, as well (n=16). 
These features may have affected our results. Previously, a correlation 
between improved outcome and CD8+ (25) or FoxP3+ (19) TILs or CD163+ 
TAMs (21) has been observed only in optimally debulked patients in some 
studies. Thus, the low R0 rate of the present study may have had an impact 
on the results. The small number of post-NACT samples (n=7) made the 
statistical analyses of this group challenging. Paired pre- and post-NACT 
specimens were not available, and therefore it was not possible to compare 
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the changes in the immune cell counts pre- and post-NACT on the same 
patient.  
 
Another limitation is that the archived FFPE samples were analyzed 
retrospectively. The patients were operated on and the samples collected 
during a long period of time (2001–2013). Some of the FFPE samples had 
to be excluded from analysis due to poor quality, which is at least partially 
due to long period of conservation. The treatment regimen, FIGO staging 
classification and the criteria for optimal cytoreduction were changed during 
the period when the patients were treated. During the recruitment period of 
the study cohort, the BRCA1/2 mutation analysis was not part of the standard 
of care and therefore the BRCA1/2 mutation status was not available in most 
cases. This should be considered when interpreting the results since 
mutation status represents a major prognostic factor in OC. 
 
In addition, multiplex IHC stainings on the same specimen were not available 
and therefore it was not possible to study the different immune cell counts or 
their ratios within the same region of the tumor tissue. 
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6 CONCLUSIONS 
 
 
Co-expression of CD8+ and granzyme B+ in TME was correlated with a 
better prognosis in HGSC, possibly by representing an activated state of 
immune system and therefore an enhanced anti-tumor immune response in 
the TME. NACT may affect the immune cell content in the TME and 
consequently the effect of immuno-oncologic treatments, as well. Further 
validation studies are needed in larger, prospective OC cohorts for 
assessment of clinical and especially the predictive significance of combined 
CD8 and granzyme B positivity as well as the effects of NACT on TME with 
WSI and DIA.  
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